Roche is looking to Phase III clinical trial results to show its Lunsumio and Columvi are the best new bispecific therapies in B-cell lymphomas, and is also highlighting patient convenience and economics as it tries to get ahead of AbbVie/Genmab’s rival CD20XCD3-targeting bispecific, Epkinly.
The company is emphasizing the benefits of its approach of using a fixed duration of treatment with Lunsumio (mosunetuzumab) in...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?